Rocket Pharmaceuticals Inc
Statements
Cash Flow
Rocket Pharmaceuticals Inc (RCKT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -40 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.1 | -11 | -12 | -5.9 | -5.6 | -3.0 | -12 | -9.7 | -12 | -21 | -16 | -18 | -11 | -20 | -22 | -22 | -17 | -13 | -24 | -40 | -28 | -31 | -39 | -39 | -44 | -56 | -58 | -51 | -57 | -29 | -57 | -54 | -52 | -47 | -56 | -49 | -50 | -35 | -45 | -40 | -170 | |
| 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | -0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.6 | 0.7 | 0.7 | 0.8 | 3.2 | 1.3 | 0.5 | 1.1 | 1.8 | 1.7 | 1.7 | 1.8 | 2.4 | 2.3 | 2.4 | 2.4 | 2.4 | 3.0 | 2.6 | 3.2 | 2.2 | 2.1 | 2.1 | 9.7 | |
| 0.8 | 0.9 | 0.1 | 0.2 | 0.7 | 1.5 | 5.4 | 2.8 | 2.6 | 2.8 | 3.2 | 4.1 | 2.7 | 3.4 | 4.0 | 4.5 | 4.0 | 6.1 | 7.9 | 7.3 | 7.0 | 7.0 | 6.3 | 7.4 | 7.7 | 9.7 | 8.9 | 10 | 10 | 9.9 | 10 | 11 | 11 | 11 | 10 | 11 | 9.8 | 6.1 | 8.5 | 7.4 | 32 | |
| 0.9 | 1.1 | 0.9 | 0.9 | 1.5 | 1.7 | 5.4 | 3.0 | 2.7 | 2.8 | 3.2 | 4.1 | 2.7 | 3.4 | 4.0 | 4.5 | 4.3 | 33 | 7.9 | 8.0 | 15 | 13 | 6.3 | 7.4 | 7.7 | 8.8 | 8.9 | 10 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.0 | 0.7 | -2.0 | -0.4 | 0.3 | 0.1 | -2.4 | 2.4 | 1.3 | 3.1 | -0.6 | -4.1 | 5.0 | -4.1 | -2.5 | -2.3 | 6.6 | 13 | 6.2 | -14 | 6.1 | -3.2 | -4.5 | 5.9 | 4.4 | 0.1 | -7.5 | 5.3 | -5.9 | 21 | -4.6 | 4.3 | 0.2 | -0.7 | -5.7 | 8.7 | -11 | 0.2 | -7.4 | 6.5 | -12 | |
| 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.5 | 0.9 | 0.8 | 6.5 | 6.7 | 9.3 | 5.8 | 4.4 | 3.9 | 15 | 0.3 | 1.5 | 3.8 | 2.0 | 2.0 | 2.9 | 0.5 | 3.3 | 3.0 | 4.1 | 4.7 | 4.6 | 2.0 | 1.9 | 1.6 | 0.3 | 0.4 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.2 | |
| 4.9 | -42 | 7.1 | 8.2 | 27 | 33 | 86 | -107 | -3.0 | 19 | 29 | -127 | 35 | 24 | 27 | -5.4 | -64 | -54 | -29 | 49 | -18 | 17 | -63 | 79 | 23 | -109 | -37 | 31 | 48 | -141 | 35 | 56 | 79 | -38 | -58 | 32 | 94 | 36 | 17 | 214 | 362 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 79 | 0.0 | 0.1 | -0.7 | – | -0.7 | 0.0 | 0.7 | -0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 1.1 | 27 | 1.1 | 0.1 | 17 | 30 | 0.0 | 18 | 0.2 | – | – | – | – | – | – | – | – | – | 0.0 | – | – | – | |
| 49 | 0.0 | – | – | – | – | – | – | – | – | – | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | – | – | 0.0 | 0.0 | – | |
| 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 25 | 79 | 0.1 | 0.1 | 75 | 75 | 85 | 0.0 | 92 | -0.1 | 0.2 | 0.5 | 282 | 8.7 | 2.4 | 27 | 1.1 | 0.1 | 17 | 30 | 108 | 18 | 0.2 | 189 | 0.4 | 1.2 | 1.6 | 0.2 | 183 | 0.0 | 0.2 | -0.1 | 0.0 | 0.0 | 0.2 | 0.1 | |
| 44 | -53 | -4.5 | 2.3 | 22 | 30 | 153 | -117 | -14 | 73 | 13 | -60 | 24 | 96 | 5.1 | -27 | -81 | 215 | -45 | 12 | -19 | -13 | -102 | 57 | 9.1 | -56 | -76 | -19 | 181 | -170 | -21 | 3.3 | 27 | 98 | -114 | -17 | 43 | 1.6 | -28 | 175 | 192 | |
| -9.2 | -11 | -12 | -5.9 | -5.6 | -3.0 | -12 | -9.8 | -12 | -22 | -17 | -25 | -18 | -29 | -28 | -26 | -21 | -28 | -25 | -41 | -32 | -33 | -41 | -42 | -44 | -59 | -61 | -55 | -62 | -34 | -59 | -56 | -54 | -47 | -56 | -49 | -50 | -35 | -45 | -40 | -170 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.